Lantheus Holdings Stock News

NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 24, 2022, to discuss its financial and operating results for the fourth quarter and full year of 2021.

NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on

Lantheus Holdings Inc. (NASDAQ:LNTH) concluded the trading at $29.41 on Thursday, December 23 with a rise of 0.89% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $29.15 and 5Y monthly beta was reading 1.30 with its price kept floating in the … A Data-Based Look At Lantheus Holdings Inc. (LNTH) Read More »

Lantheus Holdings, Inc. (NASDAQ:LNTH) Equities researchers at SVB Leerink dropped their FY2022 earnings per share (EPS) estimates for Lantheus in a research report issued to clients and investors on Tuesday, December 21st. SVB Leerink analyst D. Antalffy now forecasts that the medical equipment provider will post earnings per share of $0.86 for the year, []

Lantheus (NASDAQ:LNTH) and Global WholeHealth Partners (OTCMKTS:GWHP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Valuation & Earnings This table compares Lantheus and Global WholeHealth Partners’ gross revenue, earnings per […] The post Lantheus (NASDAQ:LNTH) versus Global WholeHealth Partners (OTCMKTS:GWHP) Head to Head Contrast appeared first on ETF Daily News .

Lantheus (NASDAQ:LNTH) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It []

Equities analysts forecast that Lantheus Holdings, Inc. (NASDAQ:LNTH) will post earnings of $0.17 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Lantheus earnings. The highest EPS estimate is $0.17 and the lowest is $0.16. Lantheus posted earnings of $0.07 per share in the same quarter last year, which []

Fisher Asset Management LLC increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 735.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 373,035 shares of the medical equipment providers stock after acquiring an additional 328,365 shares during the quarter. Fisher []

Crescent Grove Advisors LLC trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 19.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,798 shares of the medical equipment providers stock after selling 10,000 shares during the quarter. []

Wall Street brokerages forecast that Lantheus Holdings, Inc. (NASDAQ:LNTH) will report sales of $112.85 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Lantheus earnings, with estimates ranging from $112.20 million to $113.50 million. Lantheus posted sales of $94.15 million in the same quarter last year, which would indicate a [] The post $112.85 Million in Sales Expected for Lantheus Holdings, Inc. (NASDAQ:LNTH) This Quarter appeared first on ETF Daily News .

NORTH BILLERICA, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced the appointment of Vivian Yao to its Executive Team as Lantheus Chief Human Resources Officer. Ms. Yao will report directly to Lantheus President and Chief Executive Officer, Mary Anne Heino. In this role, Ms. Yao will oversee all aspects of Lantheus employee and workplace experience, including ensuring best-in-class talent processes, people operations, total rewards, organization effectiveness and next-generation HR capability.

Mitsubishi UFJ Asset Management UK Ltd. acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 20,000 shares of the medical equipment providers stock, valued at approximately $514,000. Several other hedge funds and other institutional investors have also added to or reduced their stakes in the []

PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans

PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer

Lantheus (NASDAQ:LNTH) updated its FY 2021 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.400-$0.430 for the period, compared to the Thomson Reuters consensus estimate of $0.390. The company issued revenue guidance of $405 million-$410 million, compared to the consensus revenue estimate of $396.70 million.Lantheus also updated its Q4 2021 []